Supply Chain Intelligence

Legend Biotech Corporation Supply Chain

LEGN supply chain intelligence for Legend Biotech Corporation: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

LEGN ·Last updated 2026-09-13 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

19Suppliers
30Customers
1Debt Items
20Related Chains

Source-Backed Evidence Depth

Legend Biotech Corporation (LEGN) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

52Total relationships
2Distinct source URLs
6High confidence
0.717Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Legend Biotech Corporation Suppliers

TickerNameConfidenceEvidence
GENSCRIPT GENSCRIPT 90% We rely on Genscript to provide certain services.
HEMACARE HEMACARE 85% we purchase equipment and reagents critical for the manufacture of our product candidates from Hemacare, Miltenyi, Leukapheresis Collection Center and other suppliers on a purchase order basis.
LEUKAPHERESIS-COLLECTION-CENTER LEUKAPHERESIS-COLLECTION-CENTER 85% we purchase equipment and reagents critical for the manufacture of our product candidates from Hemacare, Miltenyi, Leukapheresis Collection Center and other suppliers on a purchase order basis.
MILTENYI MILTENYI 85% we purchase equipment and reagents critical for the manufacture of our product candidates from Hemacare, Miltenyi, Leukapheresis Collection Center and other suppliers on a purchase order basis.
ALLO Allogene Therapeutics, Inc. 72% Reciprocal relationship from ALLO graph: Reciprocal relationship from LEGN graph: ct and product candidates have a limited window of stability following apheresis from a patient, we must establish an…
ALLO Allogene Therapeutics, Inc. 72% ct and product candidates have a limited window of stability following apheresis from a patient, we must establish and employ complex logistical operations, including collecting and shipping, as part…
AUTL Autolus Therapeutics plc 72% Reciprocal relationship from AUTL graph: Reciprocal relationship from LEGN graph: Reciprocal relationship from AUTL graph: Reciprocal relationship from LEGN graph: Reciprocal relationship from AUTL g…
AUTL Autolus Therapeutics plc 72% ct and product candidates have a limited window of stability following apheresis from a patient, we must establish and employ complex logistical operations, including collecting and shipping, as part…
BMYMP Bristol-Myers Squibb Co 72% Reciprocal relationship from BMYMP graph: Reciprocal relationship from LEGN graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from LEGN graph: Reciprocal relationship from BMYM…
BMYMP Bristol-Myers Squibb Co 72% ct and product candidates have a limited window of stability following apheresis from a patient, we must establish and employ complex logistical operations, including collecting and shipping, as part…
CRBU Caribou Biosciences, Inc. 72% ct and product candidates have a limited window of stability following apheresis from a patient, we must establish and employ complex logistical operations, including collecting and shipping, as part…
CRBU Caribou Biosciences, Inc. 72% Reciprocal relationship from CRBU graph: Reciprocal relationship from LEGN graph: Reciprocal relationship from CRBU graph: Reciprocal relationship from LEGN graph: ct and product candidates have a li…
FATE Fate Therapeutics, Inc. 72% Reciprocal relationship from FATE graph: Reciprocal relationship from LEGN graph: Reciprocal relationship from FATE graph: rt that a claim including items or services resulting from a violation of th…
JNJ Johnson & Johnson 72% ct and product candidates have a limited window of stability following apheresis from a patient, we must establish and employ complex logistical operations, including collecting and shipping, as part…
JNJ Johnson & Johnson 72% Reciprocal relationship from JNJ graph: Reciprocal relationship from LEGN graph: ct and product candidates have a limited window of stability following apheresis from a patient, we must establish and…
NVSEF Novartis AG 72% Reciprocal relationship from NVSEF graph: Reciprocal relationship from LEGN graph: ct and product candidates have a limited window of stability following apheresis from a patient, we must establish a…
NVSEF Novartis AG 72% ct and product candidates have a limited window of stability following apheresis from a patient, we must establish and employ complex logistical operations, including collecting and shipping, as part…
REGN Regeneron Pharmaceuticals, Inc. 72% Reciprocal relationship from REGN graph: Reciprocal relationship from LEGN graph: ct and product candidates have a limited window of stability following apheresis from a patient, we must establish an…
REGN Regeneron Pharmaceuticals, Inc. 72% ct and product candidates have a limited window of stability following apheresis from a patient, we must establish and employ complex logistical operations, including collecting and shipping, as part…

Legend Biotech Corporation Customers

TickerNameConfidenceEvidence
ALLO Allogene Therapeutics, Inc. 72% Reciprocal relationship from ALLO graph: Reciprocal relationship from LEGN graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from LEGN graph: supply chain disruptions, failure o…
ALLO Allogene Therapeutics, Inc. 72% supply chain disruptions, failure of financial institutions, rising inflation, tariffs and other world events; • comply with applicable legal and regulatory requirements; • maintain the necessary sta…
AUTL Autolus Therapeutics plc 72% Reciprocal relationship from AUTL graph: Reciprocal relationship from LEGN graph: supply chain disruptions, failure of financial institutions, rising inflation, tariffs and other world events; • comp…
AUTL Autolus Therapeutics plc 72% supply chain disruptions, failure of financial institutions, rising inflation, tariffs and other world events; • comply with applicable legal and regulatory requirements; • maintain the necessary sta…
BMY Bristol-Myers Squibb Company 72% es, and, in some cases, designed to encourage importation from other countries and bulk purchasing. We cannot predict the likelihood, nature, or extent of health reform initiatives that may arise fro…
BMY Bristol-Myers Squibb Company 72% Reciprocal relationship from BMY graph: Reciprocal relationship from LEGN graph: Reciprocal relationship from BMY graph: Reciprocal relationship from LEGN graph: es, and, in some cases, designed to e…
BMYMP Bristol-Myers Squibb Co 72% Reciprocal relationship from BMYMP graph: Reciprocal relationship from LEGN graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from LEGN graph: supply chain disruptions, failure…
BMYMP Bristol-Myers Squibb Co 72% supply chain disruptions, failure of financial institutions, rising inflation, tariffs and other world events; • comply with applicable legal and regulatory requirements; • maintain the necessary sta…
CRBU Caribou Biosciences, Inc. 72% Reciprocal relationship from CRBU graph: Reciprocal relationship from LEGN graph: supply chain disruptions, failure of financial institutions, rising inflation, tariffs and other world events; • comp…
CRBU Caribou Biosciences, Inc. 72% supply chain disruptions, failure of financial institutions, rising inflation, tariffs and other world events; • comply with applicable legal and regulatory requirements; • maintain the necessary sta…
FATE Fate Therapeutics, Inc. 72% Reciprocal relationship from FATE graph: th the GDPR and relevant local legislation in EEA Member States and the UK may be onerous and may interrupt or delay our development activities, and adversely…
GSK GSK plc 72% Reciprocal relationship from GSK graph: Reciprocal relationship from LEGN graph: y be observed in other studies; • obtain adequate and timely supply of CARVYKTI, which may in the future be adversely …
GSK GSK plc 72% y be observed in other studies; • obtain adequate and timely supply of CARVYKTI, which may in the future be adversely affected by factors relating to our manufacturing capabilities, global pandemics,…
JNJ Johnson & Johnson 72% Reciprocal relationship from JNJ graph: Reciprocal relationship from LEGN graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from LEGN graph: Reciprocal relationship from JNJ grap…
JNJ Johnson & Johnson 72% supply chain disruptions, failure of financial institutions, rising inflation, tariffs and other world events; • comply with applicable legal and regulatory requirements; • maintain the necessary sta…
NVSEF Novartis AG 72% Reciprocal relationship from NVSEF graph: Reciprocal relationship from LEGN graph: supply chain disruptions, failure of financial institutions, rising inflation, tariffs and other world events; • com…
NVSEF Novartis AG 72% supply chain disruptions, failure of financial institutions, rising inflation, tariffs and other world events; • comply with applicable legal and regulatory requirements; • maintain the necessary sta…
REGN Regeneron Pharmaceuticals, Inc. 72% Reciprocal relationship from REGN graph: Reciprocal relationship from LEGN graph: supply chain disruptions, failure of financial institutions, rising inflation, tariffs and other world events; • comp…
REGN Regeneron Pharmaceuticals, Inc. 72% supply chain disruptions, failure of financial institutions, rising inflation, tariffs and other world events; • comply with applicable legal and regulatory requirements; • maintain the necessary sta…
TCRX TScan Therapeutics, Inc. 72% Reciprocal relationship from TCRX graph: Reciprocal relationship from LEGN graph: Reciprocal relationship from TCRX graph: ding transposase enzyme, which is derived from sfR fall armyworm, to deliver…
BAC Bank of America Corporation 62% Reciprocal relationship from BAC graph: Reciprocal relationship from LEGN graph: ax laws could materially adversely affect our company and reduce net returns to our shareholders. The tax treatment of…
BOFA-SECURITIES-INC BOFA-SECURITIES-INC 62% ax laws could materially adversely affect our company and reduce net returns to our shareholders. The tax treatment of the company is subject to changes in tax laws, regulations and treaties, or the …
CAYMAN-LIMITED CAYMAN-LIMITED 62% ax laws could materially adversely affect our company and reduce net returns to our shareholders. The tax treatment of the company is subject to changes in tax laws, regulations and treaties, or the …
COORDINATION-GROUP COORDINATION-GROUP 62% or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initiatives, i…
INTERNATIONAL-MYELOMA-WORKING-GROUP INTERNATIONAL-MYELOMA-WORKING-GROUP 62% ax laws could materially adversely affect our company and reduce net returns to our shareholders. The tax treatment of the company is subject to changes in tax laws, regulations and treaties, or the …
JANSSEN-BIOTECH-INC JANSSEN-BIOTECH-INC 62% elopment and regulatory milestones, commercial sales milestones and other contingent payments, expense reimbursements, and profit-sharing. For collaboration arrangements that contain multiple element…
LEGEND-BIOTECH-USA-INC LEGEND-BIOTECH-USA-INC 62% not limited to bid price, product quality, clinical effectiveness, product safety, level of technology, qualifications and reputation of the manufacturer, after-sale services and innovation. Accordin…
NASDAQ-STOCK-MARKET-LLC NASDAQ-STOCK-MARKET-LLC 62% or our industry. For example, in February 2026, the United States Supreme Court (SCOTUS) invalidated certain tariffs imposed by the U.S. government under emergency statutory authority in 2025. Shortl…
NOVARTIS-PHARMA-AG NOVARTIS-PHARMA-AG 62% or our industry. For example, in February 2026, the United States Supreme Court (SCOTUS) invalidated certain tariffs imposed by the U.S. government under emergency statutory authority in 2025. Shortl…
NVS Novartis AG 62% Reciprocal relationship from NVS graph: Reciprocal relationship from LEGN graph: Reciprocal relationship from NVS graph: Reciprocal relationship from LEGN graph: or our industry. For example, in Febr…

Legend Biotech Corporation Debt Obligations

InstrumentDescriptionConfidenceEvidence
LEGN-DEBT Debt stack $389.3M 90% Market cache reports total debt of $389.3M.

Legend Biotech Corporation Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Legend Biotech Corporation.

Legend Biotech Corporation Ownership

HolderNameConfidenceEvidence
LEGN-OWNER-FMR-LLC FMR LLC 90% 13F overlay lists FMR LLC as top holder; 195 tracked holders.

Legend Biotech Corporation Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
BNRG Brenmiller Energy Ltd 100.00 2
CHRS Coherus Oncology, Inc. 100.00 2
BEAM Beam Therapeutics Inc. 100.00 2
BNR Burning Rock Biotech Limited 100.00 2
EDSA Edesa Biotech, Inc. 100.00 2
CSTE Caesarstone Ltd. 100.00 2
BLLN BillionToOne, Inc. 100.00 2
ANIK Anika Therapeutics, Inc. 100.00 2
BDRX Biodexa Pharmaceuticals Plc 100.00 2
ANL Adlai Nortye Ltd. 100.00 2
CTNM Contineum Therapeutics, Inc. 100.00 2
AORT Artivion, Inc. 100.00 2
AVBP ArriVent BioPharma, Inc. 100.00 2
AUTL Autolus Therapeutics plc 100.00 1 ['customer', 'supplier']
DEO Diageo plc 100.00 2
EMMA Emmaus Life Sciences, Inc. 100.00 2
BNBX BNB Plus Corp. 100.00 2
CYTOF Altamira Therapeutics Ltd. 100.00 2
BIOA BioAge Labs, Inc. 100.00 2
EDIT Editas Medicine, Inc. 100.00 2
Browse supply chain intel →

See the full supply chain map, all relationships, and real-time alerts for Legend Biotech Corporation.

Unlock full LEGN data — View plans →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map
🔐
LEGN
Unlock LEGN Supply Chain Data
Verified relationships include:
GENSCRIPTGENSCRIPTSupplier90%
HEMACAREHEMACARESupplier85%
ALLOAllogene Therapeutics, Inc.Customer72%
ALLOAllogene Therapeutics, Inc.Customer72%
+47 more relationships locked
Subscribe — View plans →
Already a subscriber? Sign in →